Spectral Doppler Ultrasound for Predicting Long‐term Response to Topical Timolol in Children with Infantile Hemangioma

Lili He,Guoying Huang

DOI: https://doi.org/10.1002/jcu.22471

2017-01-01

Journal of Clinical Ultrasound

Abstract:To assess the utility of color and spectral Doppler ultrasound at predicting infantile hemangioma (IH) response to timolol.

What problem does this paper attempt to address?

Predictors of Treatment Responses of Superficial Infantile Hemangiomas to Topical Timolol.

Hongjie Zheng,Yizuo Cai,Yuda Xu,Qian Yu,Bijun Kang,Chingyu Chen,Xia Gong,Wei Li

DOI: https://doi.org/10.1111/dth.15833

2022-01-01

Dermatologic Therapy

Abstract:Topical timolol is not effective in the treatment of some superficial infantile hemangiomas (IHs). This is a prospective study aiming to investigate the predictors of treatment response of superficial IHs to topical timolol. Patients with superficial IHs were prescribed timolol 0.5% cream four times daily and followed up every 2-3 months until 1 year of age. IH thickness was objectively measured by ultrasound, and the proportional change was calculated as a regression rate. In total, 193 patients (211 lesions) were enrolled. Topical timolol was initiated at an average age of 3.1 (0-6) months for 7.4 (2-11) months. The average regression rate of all lesions was 41.8% (-137.5%-100%). Lesion thickness (p = 0.000) and patient age at initial treatment (p = 0.001) were major variables that predicted the treatment response. On average, an increase in lesion thickness of 1 mm decreased the regression rate by 22.1%, and lesions thicker than 1.9 mm were unlikely to respond (average regression rate = -0.27%). Available results did not show a significant effect of sex (p = 0.659), lesion size (p = 0.311), or location (p > 0.05) on regression. Treatment for superficial IHs should be individualized according to lesion thickness and patient age.
Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma.

Hai Wei Wu,Chao Liu,Xuan Wang,Ling Zhang,Weien Yuan,Jia Wei Zheng,Li Xin Su,Xin Dong Fan

DOI: https://doi.org/10.3389/fonc.2017.00137

IF: 4.7

2017-01-01

Frontiers in Oncology

Abstract:The therapeutic options for infantile hemangiomas (IHs) have been greatly altered since the introduction of oral propranolol for successful treatments of IHs. Recently, there is an increase in the application of topical timolol maleate for treating superficial IHs. In the present study, we developed a new formulation of timolol maleate 0.5% hydrogel and treated 321 patients with superficial IHs to evaluate its efficacy and safety in the treatment of superficial IHs. This new timolol hydrogel was applied three times daily with a mean duration of 7.1 months. Response to treatment was assessed according to cosmetic improvement by using visual analog scale (VAS). The average VAS improvement after treatment was 76.4, with 126 patients (39.3%) achieving excellent responses, 159 patients (49.5%) achieving good responses, 33 patients (10.3%) achieving fair responses, and three patients (0.9%) achieving poor responses. Age at treatment initiation (P = 0.0349) and lesion thickness (P = 0.0147) were significantly associated with therapeutic efficacy. No severe side effects were observed in all patients. In conclusion, this new topical timolol maleate 0.5% hydrogel appears to be a proper candidate for treating superficial IHs, and our study provides supportive evidence and experience of topical timolol maleate in treating superficial IHs.
Fractional Carbon Dioxide Laser-Assisted Drug Delivery of Topical Timolol Solution for the Treatment of Deep Infantile Hemangioma: a Pilot Study.

Gang Ma,Pinru Wu,Xiaoxi Lin,Hui Chen,Xiaojie Hu,Yunbo Jin,Yajing Qiu

DOI: https://doi.org/10.1111/pde.12299

IF: 1.997

2014-01-01

Pediatric Dermatology

Abstract:Infantile hemangiomas (IHs) are benign vascular tumors of infancy. Topical timolol has recently been reported to be an effective treatment for superficial IHs, although it failed to have an effect on deep IHs. This prospective study was aimed at evaluating the feasibility of ablative fractional laser-assisted drug delivery for enhancing topical timolol permeation into deep IHs. Nine patients ages 1 to 6 months with deep IHs were enrolled. A fractional carbon dioxide (CO2 ) laser system was applied to the skin surface of deep IHs using the DeepFx mode (25-30 mJ/pulse, 5% density, single pulse) at 1-week intervals. Topical timolol maleate 0.5% ophthalmic solution was applied under occlusion for 30 minutes four to five times per day for an average treatment duration of 14.2 weeks. Clinical improvement was evaluated according to a global score and the Hemangioma Activity Score (HAS). Four patients (44.4%) demonstrated excellent regression, four (44.4%) showed good response, and one (11.1%) experienced moderate regression. The HAS declined from 4.1 ± 0.7 at baseline to 1.7 ± 0.7 at 1 week (p < 0.001) and 1.4 ± 0.7 at 3 months (p = 0.03) after the last treatment procedure. Plasma timolol concentration was not detected in any of the patients after the first administration of topical timolol. No systemic complication or skin side effects were observed in any of the patients. Ablative fractional laser-assisted transdermal delivery of topical timolol is a safe and effective method for the treatment of deep IHs.
A prospective self-controlled study of topical timolol 0.5% cream for large superficial infantile hemangiomas.

Yajing Qiu,Jingyan Yang,Minyan Chen,Lei Chang,Tianyou Wang,Gang Ma,Yunbo Jin,Hui Chen,Xiaoxi Lin

DOI: https://doi.org/10.1111/1346-8138.12786

2015-01-01

Abstract:Timolol has recently been reported to be an effective and safe treatment for small and superficial infantile hemangiomas (IH). However, it is controversial to choose it as an alternative to oral propranolol for large superficial IH. In this study, we generated a new modified timolol agent as the base of an ointment. To evaluate the efficacy and safety of this new agent, we recruited 20 patients with large superficial IH. The average age was 4months old. The average area of the IH was 28.8cm(2). The treatment was continued for 2-6months. Three assessors were asked to judge the changes in both the treated and untreated parts separately by comparing photographs. After an average of 3.25months of treatment, the average visual analog scale scores were 5.5 and 4.3 for those with and without the medication, respectively. The treated parts regressed significantly more than the untreated parts (P<0.05). There were no side-effects observed during treatment. High performance liquid chromatography was used to detect the serum concentration of timolol, and no timolol was detected in any of the blood samples (<0.02g/mL). Our new modified timolol agent is proven to be an effective therapy option for IH. Prospective studies with high-precision serum timolol concentrations, with heart rate or blood pressure monitoring during treatment, are needed to evaluate potential systemic absorption when using timolol on large IH.
Topical Timolol Vs. Oral Propranolol for the Treatment of Superficial Infantile Hemangiomas

Hai Wei Wu,Xuan Wang,Ling Zhang,Jia Wei Zheng,Chao Liu,Yan An Wang

DOI: https://doi.org/10.3389/fonc.2018.00605

IF: 4.7

2018-01-01

Frontiers in Oncology

Abstract:Objective: Infantile hemangiomas (IHs) are the most common vascular tumors of infancy. Oral propranolol has achieved great success in treating IHs since 2008. To minimize the systemic side events caused by oral administration of propranolol, topical timolol started to be applied in the treatment of IHs, especially for superficial lesions.Methods: We treated 724 children with superficial IHs using oral propranolol or topical timolol, and investigated the efficacy and safety of the two treatment patterns.Results: Both oral propranolol and topical timolol achieved a satisfactory therapeutic outcome, with an effective response rate of 97 and 96.4%, respectively. No significant differences in visual analog scale (VAS) improvement between the two groups were observed. Occurrence rate of systemic adverse events for patients treated with oral propranolol (3.9%) was significantly higher than that for patients treated with topical timolol (0%). Clinical response was not associated with gender, duration of treatment, lesion location, lesion size, gestational age, and progesterone use during pregnancy, but closely associated with age at treatment initiation, which indicated that younger age at treatment initiation predicted for a better regression rate.Conclusions: We recommend that topical timolol instead of oral propranolol could be the first-line therapy for superficial IHs because of its good efficacy and improved safety.
Prospective, Open-Label, Rater-Blinded and Self-Controlled Pilot Study of the Treatment of Proliferating Superficial Infantile Hemangiomas with 0.5% Topical Timolol Cream Versus 595-Nm Pulsed Dye Laser

Hanru Ying,Yun Zou,Wenxin Yu,Yajing Qiu,Gang Ma,Lei Chang,Yifei Gu,Dongze Lyu,Xiaoxi Lin

DOI: https://doi.org/10.1111/1346-8138.13747

2017-01-01

Abstract:Topical timolol and 595-nm pulsed dye laser (PDL) are both widely used in the treatment of superficial infantile hemangiomas (IH). However, to date, there is no reliable study comparing the therapeutic outcomes between the two treatment options. We designed the present study to evaluate and compare the efficacy and safety of timolol cream and PDL in the treatment of superficial proliferating IH. Twenty-one patients with superficial IH were included in the study. Each lesion was divided into two regions; one part was treated with 0.5% topical timolol cream four times daily, and the other part was treated monthly with PDL. Both treatments were continued for 2-6 months. Five independent and blinded assessors were asked to judge the results in both the topical timolol-treated and PDL-treated parts by comparing photographs taken before and after treatment. Both treatments resulted in significant clinical improvements after 3.39 sessions in the 2-month follow up. The average visual evaluation showed that PDL had significantly better results than topical timolol (6.55 +/- 2.26 to 4.98 +/- 2.92, P < 0.01). No patients experienced permanent side-effects during the treatment. Our short-term study revealed that PDL had better results compared with topical timolol cream application in the treatment of superficial proliferating IH. Further studies with longer follow-up time and larger sample size are required to validate our findings.
Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: a meta‐analysis of 10 studies

Huaxu Huang,Xuanfeng Chen,Beichen Cai,Jiaqi Yu,Biao Wang

DOI: https://doi.org/10.1111/dth.15907

2022-10-08

Dermatologic Therapy

Abstract:Background Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first‐line treatment of IH. We aimed to investigate the efficacy and safety of topical timolol alone or lasers plus topical timolol versus lasers alone for the treatment of IH using a meta‐analysis. Methods We searched the PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases. A more conservative random effect model meta‐analysis technique was used to analyze the efficacy and adverse reactions of timolol and lasers. Results Ten RCTs with a total of 979 patients with IH were included in this meta‐analysis. Treatment with topical timolol alone was as effective as lasers in treating IH (risk ratio [RR] = 0.99, p = 0.94), with similar adverse events. The difference was not statistically significant (RR = 1.67, p = 0.14). Combined treatment with topical timolol and lasers showed a favorable response rate compared with treatment with either lasers (RR = 1.23, p = 0.01) or topical timolol (RR = 1.35, p = 0.001) alone. Furthermore, compared to topical timolol alone, the combined treatment indicated similar risks of adverse events (RR = 0.70, p = 0.38) but fewer risks of adverse events (RR = 0.39, p = 0.004) compared to lasers alone. Conclusions This meta‐analysis provided evidences that a combined treatment with topical timolol and lasers might be more effective than a single treatment strategy in infants with IH, and with no significant increase in adverse reactions. The combination of topical timolol and laser therapy might be the preferred choice for the treatment of IHs.

dermatology
Evaluation of Transdermal Transport and Concurrent Cutaneous Hydrolysis of Timolol Prodrug for the Treatment of Infantile Hemangiomas

Shih-Jen Chang,Huiyuan Wang,Jialin Chen,Qianyi Chen,Lei Chang,Yongzhuo Huang,Yajing Qiu,Xiaoxi Lin

DOI: https://doi.org/10.3390/pharmaceutics14081607

IF: 6.525

2022-01-01

Pharmaceutics

Abstract:Infantile hemangiomas (IH) leave sequelae after involution. Topical application of timolol maleate (TM) is the mainstream treatment for superficial lesions but is limited by its low penetrable properties. We aimed to develop a superior skin permeation drug while maintaining the therapeutic properties of timolol. We predict that this drug will promote the involution of thick and deep IH lesions and avoid sequelae. We chemically modified drug structure to prepare butyryl timolol maleate (BT) prodrug and conducted in vitro and in vivo toxicity evaluations of BT with rat dorsal skin and normal skin cells. Skin permeation and absorption comparisons of TM and BT were conducted using rat and porcine skin models. Conversion efficiency of BT to timolol was also tested on human skin ex vivo. BT did not cause skin irritation on rat dorsal skin and exhibited low cytotoxicity overall. BT exhibited superior skin permeation ability compared with that of TM, whilst maintaining a low systemic absorbance. Further, BT was converted to timolol in human skin in a time-dependent manner. Noticeably, timolol accumulation in the skin from BT was higher than that from TM. Finally, BT demonstrated similar biocompatibility with TM in the IH tumor. BT enhances local delivery of timolol and its skin permeation. Using BT, we could eliminate thicker IH lesions that are prone to leave sequelae, and potentially help young children avoid dermal sequelae, disfigurement, and concomitant therapy.
Chinese Expert Consensus on the Use of Topical Timolol Maleate Treatment of Infantile Hemangiomas

Jia-Wei Zheng,Xu-Kai Wang,Cheng-Hong Jiang,Zhong-Ping Qin,Xin-Dong Fan,Yao-Wu Yang,Ran Huo,Shao-Hua Liu,Ji-Hong Zhao,Xiao-Yong Wang,De-Kai Zhou,Shao-Rong Lei

2016-01-01

Abstract:Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response. To reduce the side effects caused by systemic administration of propranolol, timolol maleate treatment has been increasingly used as an alternative to systemic β-blockers and watchful waiting for many IH patients in recent years. However, the appropriate indications, drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects still remains controversial. To standardize the use of topical timolol in treating IH, avoid overtreatment or under-treatment, as well as minimize complications, a Chinese expert consensus on the use of topical timolol treatment of IH has been approved and written by a multidisciplinary experts group based on an up-to-date literature review and repeated discussion, which can be used to reduce inappropriate variations in clinical practice and to promote the delivery of high quality, evidence-based health care for IH patients.
[Topical Timolol in the Treatment of Periocular Superficial Infantile Hemangiomas: a Prospective Study].

Xiao-xiao Ye,Yun-bo Jin,Xiao-xi Lin,Gang Ma,Xiao-dong Chen,Ya-jing Qiu,Hui Chen,Xiao-jie Hu

DOI: https://doi.org/10.3760/cma.j.issn.1009-4598.2012.03.001

2012-01-01

Abstract:OBJECTIVE:To investigate the efficacy and side effect of topical beta-blocker (Timolol Maleate) in the treatment of periocular hemangioma in a prospective study.METHODS:432 outpatients with infantile hemangioma visited our special clinic service in Shanghai Ninth People's Hospital from July 2010 to December 2011. Among them, 12 superficial periocular lesions were selected in the study. Timolol was used topically on the lesion in every 12 hours. Two independent special doctors evaluated the results according to the pictures before and after four-week application of timolol.RESULTS:Were categorized into four levels: continuous growth (the lesion continues to grow), stable (no visible change), moderate (0-50% of regression) , perfect (more than 50% of improvement). Result of the 12 outpatients, 4 showed perfect result, 2 moderate, 4 stable and 2 continuous growth. No side effect was observed.CONCLUSIONS:Topical timolol is effective and safe in the treatment of superficial periocular infantile hemangioma. It could be considered as the first line treatment of proliferative superficial hemangioma.
Effect of Timolol Maleate Gel-forming Solution in the Treatment of Superficial Infantile Hemangiomas: a Prospective, Randomized, Double-Blind, Controlled Trial

chou yajing,chen minyan,chang lei,ma gang,hu xiaojie,jin yunbo,chen hui,lin xiaoxi

DOI: https://doi.org/10.3969/j.issn.1673-0364.2014.04.009

2014-01-01

Abstract:Objective To investigate the efficacy and safety of timolol maleate gel-forming solution with different concentrations for the treatment of superficial infantile hemangiomas(IHs). Methods From July 2012 to February 2013,patients aged from 1 to 6 months with superficial infantile hemangiomas were enrolled onto this study: a prospective, randomized,double-blind, controlled trial. Participants were randomly divided into 3 groups according to different concentration of timolol maleate gel-forming solution: group 1(0.25% timolol gel), group 2(0.5% timolol gel) and group 3(1.0% timolol gel). Adverse effects and duration of the treatments were recorded. A visual analogue scale(VAS) was used to evaluate the efficacy of the drugs. Multiple logistic regression analysis was used to determine the independent correlation of each factor(e.g. age, gender,tumors location, the thickness of tumor, drug concentration, application frequency and duration of the treatment) and the efficacy.Results The mean VAS score was 30.94±32.97 for the patients treated by timolol gels with a total clinical efficacy of 62.3%.There were significant correlations between the VAS scores and the frequency & the duration of treatment(P<0.05). The main side effects were local skin reactions(2.9%) and mild wheezing(0.97%). Conclusion Timolol gel is safe and effective in the treatment for superficial IHs. Concentrations are not relevant for the treatment effect.
Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas

Kun Han,Jingjian Wei,Hao Zheng,Xiaodong Li,Aixia Zhang,Yanhong Ma,Jian Meng,Yuanyuan Hu

DOI: https://doi.org/10.1097/scs.0000000000010001

2024-02-12

Journal of Craniofacial Surgery

Abstract:Infantile hemangiomas (IHs) are the most common benign soft tissue tumors of infancy. Oral propranolol has become a first-line treatment option since the unexpected discovery of its surprising efficacy in the treatment of IHs in 2008. However, oral propranolol causes systemic complications, including hypotension, bradycardia, and hypoglycemia. To minimize systemic adverse effects of oral propranolol, timolol maleate, a nonselective β-blocker similar to propranolol, has been used as a topical agent to treat superficial IHs. The authors evaluated the efficacy and safety of oral propranolol or topical timolol in 60 patients with IHs. Of the 60 patients recruited, 30 patients were treated using orally administrated propranolol and an additional 30 patients received topical timolol. The efficacy rate of the oral propranolol and topical timolol was 96.7% and 93.3%, respectively. There were no significant differences between the two treatment patterns for the efficacy rate. The incidence of systemic adverse effects for patients treated with oral propranolol was significantly higher than that for cases received topically timolol treatment. Topical timolol maleate is effective and well-tolerated in the treatment of IHs. It could be considered as the first-line treatment choice, especially for superficial IHs.

surgery
Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study

Jing Ge,Jiawei Zheng,Ling Zhang,Weien Yuan,Haiguang Zhao

DOI: https://doi.org/10.1038/srep19765

IF: 4.6

2016-01-28

Scientific Reports

Abstract:AbstractCompound infantile hemangiomas (IHs) are problematic and usually require intervention. This retrospective study aimed to introduce a combined therapy of oral propranolol and topical timolol and evaluate its efficacy and safety. Eighty-nine infants with compound IHs were treated with oral propranolol 2 mg/kg/day divided 2 times per day and timolol maleate 0.5% gel 3 times per day, for at least 3 months. Two observers evaluated the hemangioma independently at 0, 1, 3, 6, 9 months after the initiation of treatment. Changes in the hemangioma score values were evaluated using paired t test. Rebound growth and adverse effects were recorded. After treatment was completed, this combined therapy achieved clinical response in 100% of the patients (89/89). Significant positive effects were demonstrated at 1, 3, 6 months (p < 0.001), but not obvious after 6 months (p = 0.06). The response of IHs to the therapy was depending on the age at initial treatment. The average treatment duration was 6.48 (5.77–7.19) months. One patient (1.1%) relapsed after cessation of 6-month treatment and 7 children (7.8%) developed side effects. Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment.

multidisciplinary sciences
Oral Propranolol Combined with Topical Timolol for Compound Infantile Hemangiomas: Results in 89 Consecutive Patients

J.W. Zheng,J. Ge,L. Zhang,W.E. Yuan

DOI: https://doi.org/10.1016/j.ijom.2015.08.901

IF: 2.986

2015-01-01

International Journal of Oral and Maxillofacial Surgery

Abstract:Background: Infantile hemangiomas (IHs) are the most common benign vascular tumors in infancy; the treatment algorithm and methods for IHs have been greatly changed in recent years.
Open-Label Nonrandomized Left-Right Comparison of Imiquimod 5% Ointment and Timolol Maleate 0.5% Eye Drops in the Treatment of Proliferating Superficial Infantile Hemangioma

Li Hu,Hui Zhen Huang,Xin Li,Xiao Xi Lin,Wei Li

DOI: https://doi.org/10.1159/000369164

2015-01-01

Dermatology

Abstract:Background: Infantile hemangiomas (IHs) are common childhood tumors. Objective: Our study aimed to compare the efficacy and side effects of imiquimod and timolol maleate for the treatment of proliferating superficial IHs. Methods: A total of 54 patients with superficial IHs were enrolled in this study. Each lesion was evenly divided into two parts. One part was treated with 5% imiquimod cream once every other day, and the other part was smeared with 0.5% timolol maleate eye drops thrice daily. After 16 weeks of treatment, the thickness, color and size of each lesion were measured, and the side effects were recorded. Results: The efficacy rates for imiquimod and timolol maleate were 81.4 and 88.9%, respectively, but the difference between treatments was not significant. However, timolol maleate showed better effects for color involution, onset time and side effects than imiquimod. Conclusion: Timolol maleate might be the first choice for the topical treatment of superficial IHs.
The therapeutic effects of propranolol combined with timolol eye drops in the treatment of infantile he￣mangioma

林雀卿,张靖,姜华,申刚,周少毅,陈昆山,李海波,牛传强,谭小云

2014-01-01

Abstract:Objective:To assess the efficacy and safety of propranolol combined with timolol eye drops in the treatment of infantile hemangioma ( IH) . Methods:One hundred and thirty patients were treated with oral propranolol 2 mg/( kg.d) , 3 times a day and topical timolol eye drops, 4 times a day for 3 months. Results:The size of tumors was reduced by 26%~50% in 66 ( 49%) patients, by 51%~75% in 53 ( 42%) patients, by 26%~50% in 10 ( 8%) patients and by 1% in one ( 1%) patient. There were no obvious adverse reac￣tions. Conclusion:Propranolol combined with timolol eye drops is effective and safe in the treatment of IH.
Comparison of Oral Propranolol Alone and Combined with Topical 0.5 ％ Timolol Maleate Cream for the Treatment of Infantile Hemangiomas

Yu Qian,Xu Peng,Huang Huizhen,Cai Yizuo,Zheng Hongjie,Xu Yuda,Li Wei

DOI: https://doi.org/10.3760/cma.j.issn.1009-4598.2019.02.008

2019-01-01

Abstract:Objective To investigate whether the combination of oral propranolol and topical 0.5％ timolol maleate cream is more effective than oral propranolol alone for treating infantile hemangioma (IH).Methods From September 2015 to July 2016,14 patients with proliferative IH,visited the infantile hemangioma outpatient clinic of the Department of Plastic and Reconstructive Surgery of Shanghai 9th People's Hospital,were enrolled in this study.All patients took oral propranolol.Half of each IH lesion was treated with 0.5％ timolol maleate cream.There were 5 male patients and 9 female patients,aged from 1.5 to 5.0 months.After 4 months of treatment,the color,size,extent,volume and the overall clinical outcomes of each lesion were measured,and the side effects were recorded.The therapeutic outcomes of oral propranolol alone and the combination of propranolol and timolol were analyzed and compared using Wilcoxon matched-pair signed-rank nonparametric tests.Results Both oral propranolol alone and oral propranolol combined with topical 0.5％ timolol maleate cream were proved to effectively improve the regression of IH with minor side effects.The color VAS score of oral propranolol alone group was 6.92± 2.63,while the combination group was 6.88±2.33 (Z=0.043,P=0.966).The volume VAS score of oralpropranolol alone group was 6.94 ± 2.00,while the combination group was 6.98 ± 2.11 (Z =-0.051,P =0.959).Conclusions Oral propranolol combined with topical application of 0.5％ timolol maleate could not increase the efficacy in the treatment of IH,compared with oral propranolol alone in the short-term observation.
The Effect of 0.5% Topical Timolol Cream on Regression of Superficial Infantile Haemangioma in the Involuting Phase: a Prospective, Randomized, Self-Controlled Study

Ying Hanru,Han Yue,Chen Zongan,Yu Zhang,Chang Lei,Ma Gang,Chen Qianyi,Chang Shihjen,Qiu Yajing,Lin Xiaoxi

DOI: https://doi.org/10.1684/ejd.2020.3708

2020-01-01

European Journal of Dermatology

Abstract:Infantile haemangiomas are the most common benign tumours affecting infants. Over time, the tumours may involute to some extent. However, sequelae, such as telangiectasia or fibrofatty tissue, often occur following this condition, which may cause disfigurement and influence patients’ psychosocial development. This prospective, randomized, self-controlled study aimed to assess the effects of topical timolol (0.5%) on involuting infantile haemangiomas. Each involuting superficial infantile haemangioma (n = 29) was randomly divided into two regions; one region was treated with topical timolol (0.5%) cream, three times daily, and the other region was untreated. The comparative treatments continued for three months. Five independent assessors, blinded to the treatment regimen, judged the treated and untreated regions by comparing photographs before and after treatment. The topical timolol-treated tumour sections showed no difference compared with the untreated sites (p = 0.355) after three months of treatment, and by the end of the treatment, the untreated lesions showed significant differences relative to pre-treatment (p<0.001). Topical timolol was not observed to have any effect on the regression of infantile haemangiomas in the involuting phase.
Imiquimod 5% Cream Versus Timolol 0.5% Ophthalmic Solution for Treating Superficial Proliferating Infantile Haemangiomas: a Retrospective Study

Y. Qiu,G. Ma,J. Yang,X. Hu,H. Chen,Y. Jin,X. Lin

DOI: https://doi.org/10.1111/ced.12150

2013-01-01

Clinical and Experimental Dermatology

Abstract:BACKGROUND:Infantile haemangiomas (IHs) are the most common vascular tumours of infancy. Topical therapies are a possible treatment for superficial IHs.AIM:To determine the efficacy and safety of topical therapy in the treatment of superficial proliferating IHs.METHODS:The medical records of all the patients with proliferating superficial IHs were reviewed. All lesions had been treated either with imiquimod 5% cream or timolol 0.5% ophthalmic solution. Lesions were classified into pairs, with one of each treatment in each pair, matched by anatomical location, colour and size. A visual analogue scale (VAS) and the Haemangioma Activity Score (HAS) were used to evaluate the efficacy of the two drugs. The paired Student t-test was used to test for differences in recovery with these two treatments.RESULTS:In total, 51 patients treated with timolol and 94 treated with imiquimod met the inclusion criteria, and 20 lesions treated with timolol were successfully matched to a lesion treated with imiquimod. The paired t-test indicated that there was no significant difference in either VAS score (P = 0.11) or HAS (P = 0.49). For the imiquimod-treated patients, crusting was the most common reaction (65.0%, 13/20). This did not cause any superficial scarring or skin pigmentation in the matched pairs; however, superficial scars (14.9%, 14/94) and skin pigmentation disorders (28.7%, 27/94) were reported for some of the unmatched cases. There were no adverse events (AEs) during the treatment with timolol.CONCLUSIONS:Both imiquimod 5% cream or timolol 0.5% ophthalmic solution showed equivalent clinical efficacy after 4 months of treatment. Timolol appeared to have fewer AEs than imiquimod in the management of superficial IHs. Larger, prospective controlled trials with long-term treatment are needed to confirm these results.
Comparison of Simply Topical Timolol 0.5% Cream and Combined with Intralesional Diprospan Injection for the Treatment of Thick Superficial Infantile Hemangiomas

huang huizhen,li wei,yu qian,ma gang,chou yajing,chang lei,jin yunbo,lin xiaoxi

DOI: https://doi.org/10.3969/j.issn.1673-0364.2016.05.011

2016-01-01

Abstract:Objective To compare the efficacy and safety of simply topical timolol 0.5% cream and timolol combined with intralesional Diprospan in the treatment of thick superficial infantile hemangiomas(IH). Methods From January to November 2015, 43 patients with thick superficial IH(2 ~6 mm) were recruited for a self-control study. Half lesion was treated with topical timolol 0.5% cream simply, while the other was treated with topical timolol 0.5% cream combined with Diprospan injection. Cream was applied four times daily for five months, and the injection of Diprospan was given every 4weeks. The injection time depended on tumor thickness and the effect, when the depth of lesion was less than 2 mm or no further improvement was observed after three treatment procedures, injection treatment should be stopped. Finally, according to the thickness, the color and area score, the effective rate and the incidence rate of adverse reaction were compared between the two groups. Results Thirty-eight patients with thirty-night lesions finished the research. The efficacy rates of topical timolol group and combined treatment group were 92.3% and 97.4%, no significant difference was observed. The combined treatment group exhibited better effect than timolol cream group, especially in the involution of thickness, color and onset time, while not in the involution of area. The side effects included ulceration(5.13%) and soft tissue atrophy(5.13%)were observed in combined treatment group and peeling(2.56%) in both group. Conclusion Compared with simply topical cream, intralesional Diprospan combined with topical timolol 0.5% cream has a better effect for treating superficial IH with a certain protruding degree in the aspects of thickness, color and onset time.

Spectral Doppler Ultrasound for Predicting Long‐term Response to Topical Timolol in Children with Infantile Hemangioma

Predictors of Treatment Responses of Superficial Infantile Hemangiomas to Topical Timolol.

Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma.

Fractional Carbon Dioxide Laser-Assisted Drug Delivery of Topical Timolol Solution for the Treatment of Deep Infantile Hemangioma: a Pilot Study.

A prospective self-controlled study of topical timolol 0.5% cream for large superficial infantile hemangiomas.

Topical Timolol Vs. Oral Propranolol for the Treatment of Superficial Infantile Hemangiomas

Prospective, Open-Label, Rater-Blinded and Self-Controlled Pilot Study of the Treatment of Proliferating Superficial Infantile Hemangiomas with 0.5% Topical Timolol Cream Versus 595-Nm Pulsed Dye Laser

Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: a meta‐analysis of 10 studies

Evaluation of Transdermal Transport and Concurrent Cutaneous Hydrolysis of Timolol Prodrug for the Treatment of Infantile Hemangiomas

Chinese Expert Consensus on the Use of Topical Timolol Maleate Treatment of Infantile Hemangiomas

[Topical Timolol in the Treatment of Periocular Superficial Infantile Hemangiomas: a Prospective Study].

Effect of Timolol Maleate Gel-forming Solution in the Treatment of Superficial Infantile Hemangiomas: a Prospective, Randomized, Double-Blind, Controlled Trial

Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas

Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study

Oral Propranolol Combined with Topical Timolol for Compound Infantile Hemangiomas: Results in 89 Consecutive Patients

Open-Label Nonrandomized Left-Right Comparison of Imiquimod 5% Ointment and Timolol Maleate 0.5% Eye Drops in the Treatment of Proliferating Superficial Infantile Hemangioma

The therapeutic effects of propranolol combined with timolol eye drops in the treatment of infantile he￣mangioma

Comparison of Oral Propranolol Alone and Combined with Topical 0.5 ％ Timolol Maleate Cream for the Treatment of Infantile Hemangiomas

The Effect of 0.5% Topical Timolol Cream on Regression of Superficial Infantile Haemangioma in the Involuting Phase: a Prospective, Randomized, Self-Controlled Study

Imiquimod 5% Cream Versus Timolol 0.5% Ophthalmic Solution for Treating Superficial Proliferating Infantile Haemangiomas: a Retrospective Study

Comparison of Simply Topical Timolol 0.5% Cream and Combined with Intralesional Diprospan Injection for the Treatment of Thick Superficial Infantile Hemangiomas